A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB)

Researchers have discovered a molecular pathway in colorectal cancer cells that leads to uncontrolled division, creating an avenue for more targeted therapies.

Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.

By analysing heart cells, a new machine learning algorithm could help predict arrhythmia risk before symptoms appear.

In 2023, the National Research Foundation Singapore selected 10 A*STAR researchers to be a part of its competitive Investigatorship and Fellowship grant programmes.

Scalable and cost-effective methods for growing fat cells pose a commercialisation barrier for cultivated meat products.

After three decades as one of Singapore’s biomedical research pioneers, PSTA 2022 medallist Wanjin Hong reflects on his seminal work in the molecular biology of cancers, as well as the country’s evolving research landscape.

A*STAR scientists decipher how a stem cell-based treatment stops the uncontrolled inflammation associated with severe COVID-19 cases.

A T cell therapy innovation may offer new hope for acute myeloid leukemia patients who relapse after conventional treatment.

A new polymer gel may offer a drug-free solution to preventing retinal scarring after eye surgery.

Scientists discover a potential therapeutic target to tackle a dangerous drug-resistant yeast strain.

A protein called Agrin naturally produced in the skin could soon be the active ingredient in a treatment to boost skin repair in non-healing wounds.

Multidisciplinary efforts across A*STAR are paving the way toward Singapore’s precision medicine vision.